Drugs: pegcetacoplan
FDA Approves Syfovre: First Treatment for Geographic Atrophy
Syfovre has received FDA approval as the first-ever treatment for geographic atrophy, marking a significant advancement in managing this debilitating condition.
Executive Summary
- Syfovre has received FDA approval as the first-ever treatment for geographic atrophy, marking a significant advancement in managing this debilitating condition.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: March 31, 2026
The U.S. Food and Drug Administration (FDA) has approved pegcetacoplan (Syfovre) injection for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), marking a historic milestone as the first approved therapy for this progressive, vision-threatening condition. The approval, announced on February 17, 2023, provides a new treatment option for the approximately one million Americans living with GA, a leading cause of blindness.
Developed by Apellis Pharmaceuticals, pegcetacoplan is administered as a monthly or every-other-month intravitreal injection and works by targeting excessive activation of the complement cascade, specifically inhibiting C3, which plays a central role in GA progression.
Clinical Evidence Supporting Approval
The FDA's decision was based on positive results from the DERBY and OAKS Phase 3 clinical trials (NCT03525600 and NCT03525613), which collectively enrolled 1,258 patients with GA. The studies demonstrated that pegcetacoplan significantly reduced GA lesion growth compared to sham treatment.
Key efficacy data from the trials showed:
- Monthly treatment reduced GA lesion growth by 21% (p=0.0003) over 24 months
- Every-other-month dosing showed a 17% reduction (p=0.0052) in lesion growth
- Treatment effects were observed as early as 6 months and increased over time
Safety Profile
The safety profile was consistent with previous studies, with the most common adverse events including:
- Ocular injection site reactions (15%)
- Conjunctival hemorrhage (13%)
- Increased intraocular pressure (9%)
Disease Background and Unmet Need
Geographic atrophy represents an advanced form of dry AMD characterized by progressive degeneration of retinal cells, leading to irreversible vision loss. Prior to pegcetacoplan's approval, there were no FDA-approved treatments available, highlighting the significant unmet medical need addressed by this approval.
Market Impact and Access
Apellis Pharmaceuticals has announced that pegcetacoplan will be commercially available in early March 2023 through specialty distributors and specialty pharmacies. The company estimates that approximately 1 million people in the United States have GA, with over 150,000 new cases diagnosed annually.
Expert Commentary
According to Dr. Jeffrey S. Heier, principal investigator of the DERBY study and Director of the Retinal Service and Retinal Research at Ophthalmic Consultants of Boston, "The approval of pegcetacoplan represents a paradigm shift in how we treat geographic atrophy. For the first time, we have the ability to slow the relentless progression of this disease with a treatment that has demonstrated a favorable safety profile in clinical trials."
Frequently Asked Questions
What is geographic atrophy?
Geographic atrophy is an advanced form of age-related macular degeneration characterized by progressive damage to the retina, leading to irreversible vision loss.
How is pegcetacoplan administered?
Pegcetacoplan is administered as an intravitreal injection either monthly or every other month, based on the healthcare provider's assessment and patient factors.
Who is eligible for pegcetacoplan treatment?
The treatment is approved for adults with geographic atrophy secondary to age-related macular degeneration. Specific patient selection criteria should be discussed with an eye care provider.
Looking Ahead
Apellis Pharmaceuticals has indicated plans for post-marketing studies to further evaluate long-term safety and effectiveness. The company is also investigating potential expanded indications and combination approaches with other therapeutic modalities.
The approval of pegcetacoplan represents a significant advancement in the treatment of geographic atrophy, providing hope for patients who previously had no FDA-approved treatment options. As the first therapy in this space, it sets a new standard for future developments in the management of this devastating condition.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-03-31.
